The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score

Abstract

Treatment with abiraterone acetate and prednisone (compared with treatment with prednisone only) for metastatic castration-resistant prostate cancer increased survival in all patients in the study regardless of pain, prostate-specific antigen levels at the start of treatment, and Gleason score at primary diagnosis.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study

“…One of the purposes of the STABEN trial was to assess whether the potential advantage associated with statin use could be related to their known cardiovascular and cerebrovascular protective effect, of particular potential importance in an elderly population receiving abiraterone – an agent with known cardiovascular toxicity [ 22 ]. In the present retrospective study, multivariable models that included known prognostic factors in prostate cancer (e.g., baseline PSA levels, hemoglobin levels, Gleason score, alkaline phosphatase and LDH levels [ 23 ], visceral involvement [ 24 ] and neutrophil to lymphocyte ratio [ 25 ]) revealed that statin use was associated with a 53% reduction in the risk of all-cause mortality, and a 57% reduction in the risk of prostate cancer-specific mortality. It also appeared that statin co-administration increased the odds of having an early >30% PSA decrease, which is consistent with our previously reported findings and adds strength to the hypothesis of a potential synergism with abiraterone/enzalutamide.…”

Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real‐world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

“…Other issues discussed in relation to mCRPC included the following: whether the clinical benefits of starting treatment for mCRPC earlier (e.g. whilst patients are asymptomatic or have a lower Gleason score or PSA level) are sufficient to justify the additional cost. a comparison of approaches used across the region to manage skeletal‐related events in men with mCRPC receiving ADT. …”

“…Other issues discussed in relation to mCRPC included the following: [32] are sufficient to justify the additional cost.…”

Frühe vs. spätere Therapie mit Abirateron plus Prednison bei chemotherapie-naiven, asymptomatischen bis mild symptomatischen Patienten mit metastasiertem CRPC nach Androgendeprivation

“…Ein Unterschied zwischen FTh-und STh-Patienten ergab sich aber für das Gesamtüberleben (OS). Diese Ergebnisse stehen im Gegensatz zur COU-AA-302-Posthoc-Analyse, bei der OS, rPFS, Zeit bis zur Chemotherapie und Zeit bis zum Opioidgebrauch bei asymptomatischen mCRPC-Patienten mit PSA-Werten < 80 ng/ ml zu Beginn der Behandlung und einem GS von < 8 bei Primärdiagnose im Vergleich zu Patienten mit fortgeschrittenem PSA oder Schmerzniveau oder einem GS von ≥ 8 länger waren [19].…”